

2017 Focused Update of the 2016 ACC Expert Consensus
Document on Non-Statin Therapies for LDL-Cholesterol Lowering in
Patients with Cardiovascular Disease Risk

Journal of the American College of Cardiology
70, 1785-1822

DOI: [10.1016/j.jacc.2017.07.745](https://doi.org/10.1016/j.jacc.2017.07.745)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Monoclonal Antibodies for Lipid Management. <i>Current Atherosclerosis Reports</i> , 2016, 18, 39.	2.0	6
2	Diagnosis and treatment of high density lipoprotein deficiency. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 97-106.	1.6	63
3	Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 923-932.	0.6	10
4	PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 7-32.	1.0	41
5	A Clinical Guide to Combination Lipid-Lowering Therapy. <i>Current Atherosclerosis Reports</i> , 2018, 20, 19.	2.0	21
6	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1397-1408.	2.6	83
7	The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia. <i>Annals of Pharmacotherapy</i> , 2018, 52, 1000-1018.	0.9	21
8	Diabetes and lipid metabolism. <i>Hormones</i> , 2018, 17, 61-67.	0.9	192
9	Daily melatonin protects the endothelial lineage and functional integrity against the aging process, oxidative stress, and toxic environment and restores blood flow in critical limb ischemia area in mice. <i>Journal of Pineal Research</i> , 2018, 65, e12489.	3.4	68
10	Statin loading in cardiovascular surgery. <i>Current Opinion in Cardiology</i> , 2018, 33, 436-443.	0.8	27
11	Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease. <i>Circulation</i> , 2018, 138, 756-766.	1.6	200
12	Novedades en el tratamiento mdico de la cardiopata isqumica estable. <i>CardiCore</i> , 2018, 53, 101-105.	0.0	2
13	Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease—Real-world experience within a large integrated health care system: The IMPRES study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1008-1018.e1.	0.6	8
14	Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. <i>Atherosclerosis</i> , 2018, 269, 219-228.	0.4	67
15	Recent Approaches to Improve Medication Adherence in Patients with Coronary Heart Disease: Progress Towards a Learning Healthcare System. <i>Current Atherosclerosis Reports</i> , 2018, 20, 5.	2.0	30
16	Biomarker definitions and their applications. <i>Experimental Biology and Medicine</i> , 2018, 243, 213-221.	1.1	722
17	PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option. <i>Postgraduate Medicine</i> , 2018, 130, 287-298.	0.9	8
18	The pharmacological management of metabolic syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 397-410.	1.3	80

#	ARTICLE	IF	CITATIONS
19	Evolving Role of Non-Statins for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. <i>Pharmacotherapy</i> , 2018, 38, 164-171.	1.2	7
20	Inflammation and Cardiovascular Disease Risk: A Case Study of HIV and Inflammatory Joint Disease. <i>American Journal of Medicine</i> , 2018, 131, 442.e1-442.e8.	0.6	4
21	2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 201-230.	1.2	235
22	Nutraceuticals in endocrine disorders. <i>Nature Reviews Endocrinology</i> , 2018, 14, 68-70.	4.3	7
23	LDL cholesterol: How low to go?. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 348-354.	2.3	12
24	The year in cardiology 2017: prevention. <i>European Heart Journal</i> , 2018, 39, 345-353.	1.0	3
25	Optimizing Statins and Ezetimibe in Guideline-Focused Management. <i>Cardiology Clinics</i> , 2018, 36, 221-223.	0.9	3
26	Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. <i>International Journal of Cardiology</i> , 2018, 261, 183-188.	0.8	95
28	Medical Expenditures Among Medicare Beneficiaries with Statin-Associated Adverse Effects Following Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 601-610.	1.3	8
29	2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3200-3223.	1.2	251
30	Basic Considerations for the Use of Monoclonal Antibodies in Migraine. <i>Headache</i> , 2018, 58, 1689-1696.	1.8	22
31	Medication-based versus target-based lipid management. <i>Journal of Diabetes</i> , 2018, 10, 789-792.	0.8	1
33	Nonadherence to statins: individualized intervention strategies outside the pill box. <i>Vascular Health and Risk Management</i> , 2018, Volume 14, 91-102.	1.0	44
34	Dyslipidemias in clinical practice. <i>Clinica Chimica Acta</i> , 2018, 487, 117-125.	0.5	26
35	Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies. <i>Current Cardiology Reports</i> , 2018, 20, 125.	1.3	15
36	Realizing Value With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. <i>Circulation</i> , 2018, 138, 767-769.	1.6	2
37	Dietary Nitrate from Beetroot Juice for Hypertension: A Systematic Review. <i>Biomolecules</i> , 2018, 8, 134.	1.8	50
38	Medical and lifestyle management of peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2018, 68, 1595-1606.	0.6	44

#	ARTICLE	IF	CITATIONS
39	Lipid management in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 727-749.	4.1	153
40	Evidence-Based Management of Diabetes in Older Adults. <i>Drugs and Aging</i> , 2018, 35, 1065-1078.	1.3	19
41	Beyond Statins: Who and When to Prescribe?. <i>Current Diabetes Reports</i> , 2018, 18, 126.	1.7	4
42	Comparison of Lipid-Lowering Medications and Risk for Cardiovascular Disease in Diabetes. <i>Current Diabetes Reports</i> , 2018, 18, 138.	1.7	4
43	Safety and efficacy of statin therapy. <i>Nature Reviews Cardiology</i> , 2018, 15, 757-769.	6.1	239
45	Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. <i>Journal of Lipid Research</i> , 2018, 59, 2421-2435.	2.0	49
46	Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 116.	1.1	7
47	Lipids: a personal view of the past decade. <i>Hormones</i> , 2018, 17, 461-478.	0.9	5
48	Impact of Combination Therapy with Ezetimibe/Simvastatin Treatment on the Neointimal Response to Biodegradable Polymer Biolimus-Eluting Stent Implantation in Patients with Acute Myocardial Infarction: Serial Assessment with Optical Coherence Tomography. <i>Applied Sciences (Switzerland)</i> , 2018, 8, 1968.	1.3	1
49	Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2389-2398.	2.2	19
50	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. <i>Diabetes Therapy</i> , 2018, 9, 1317-1334.	1.2	21
51	Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. <i>Current Cardiology Reports</i> , 2018, 20, 55.	1.3	6
52	PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?. <i>Journal of Clinical Lipidology</i> , 2018, 12, 844-848.	0.6	1
53	Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service. <i>Journal of Clinical Lipidology</i> , 2018, 12, 999-1007.	0.6	6
54	12-year trends in cardiovascular risk factors (2002-2005 through 2011-2014) in patients with cardiovascular diseases: Tehran lipid and glucose study. <i>PLoS ONE</i> , 2018, 13, e0195543.	1.1	12
55	Effectiveness and Safety of Inclisiran, A Novel Long-Acting RNA Therapeutic Inhibitor of Proprotein Convertase Subtilisin/Kexin 9. <i>American Journal of Cardiology</i> , 2018, 122, 1272-1277.	0.7	19
56	Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels. <i>JAMA Cardiology</i> , 2018, 3, 823.	3.0	158
57	Calculating LDL cholesterol in familial combined hyperlipidemia: Out with the old, in with the new?. <i>Atherosclerosis</i> , 2018, 277, 172-174.	0.4	3

#	ARTICLE	IF	CITATIONS
58	Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. <i>Frontiers in Pharmacology</i> , 2018, 9, 707.	1.6	31
59	Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 44.	1.0	3
60	CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 44.	1.0	10
61	Comparison of the 2017 Taiwan lipid guidelines and the Western lipid guidelines for high risk patients. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 853-859.	0.6	7
62	Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials. <i>Atherosclerosis</i> , 2018, 277, 211-218.	0.4	10
63	Fluorescence biosensor based on gold-carbon dot probe for efficient detection of cholesterol. <i>Synthetic Metals</i> , 2018, 244, 92-98.	2.1	23
64	Dose-dependent INhibitory effect of rosuVastatin In Japanese patienTs with Acute myocardial infarcTION on serum concentration of matrix metalloproteinases â€“ INVITATION trial. <i>Journal of Cardiology</i> , 2018, 72, 350-355.	0.8	3
65	Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 419-429.	0.6	7
66	Consistent LDLâ€™ response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. <i>Clinical Cardiology</i> , 2018, 41, 1328-1335.	0.7	25
67	Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study. <i>Scientific Reports</i> , 2018, 8, 11925.	1.6	8
68	National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	21
69	Determinants of Achieved LDL Cholesterol and â€™Non-HDLâ€™ Cholesterol in the Management of Dyslipidemias. <i>Current Cardiology Reports</i> , 2018, 20, 60.	1.3	8
70	Lowering <sc>LDL</sc>â€™Cholesterol and <sc>CV</sc> Benefits: Is There a Limit to How Low <sc>LDL</sc>â€™ Needs to be for Optimal Health Benefits?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 290-296.	2.3	6
71	Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation. <i>JAMA Cardiology</i> , 2018, 3, 749.	3.0	105
72	Measuring Low-Density Lipoprotein Cholesterol. <i>JAMA Cardiology</i> , 2018, 3, 754.	3.0	0
73	Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 747-754.	0.5	2
74	Midlife Hypertension and Alzheimerâ€™s Disease: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 307-316.	1.2	91
75	More- Versus Less-Intensive Lipid-Lowering Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005460.	0.9	8

#	ARTICLE	IF	CITATIONS
76	2019 Methodology for Creating Expert Consensus Decision Pathways. Journal of the American College of Cardiology, 2019, 74, 1138-1150.	1.2	25
77	Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. Current Cardiology Reports, 2019, 21, 110.	1.3	24
78	Nutraceuticals: Reviewing their Role in Chronic Disease Prevention and Management. Pharmaceutical Medicine, 2019, 33, 291-309.	1.0	23
79	Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older. JAMA Cardiology, 2019, 4, 846.	3.0	81
80	PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice. Drugs - Real World Outcomes, 2019, 6, 115-123.	0.7	17
81	Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition. Current Diabetes Reports, 2019, 19, 61.	1.7	44
82	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. Clínica E Investigaci3n En Arteriosclerosis (English Edition), 2019, 31, 128-139.	0.1	6
83	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal, 2022, 43, e17-e25.	1.0	92
84	Matters of the Heart. Obstetrics and Gynecology Clinics of North America, 2019, 46, 515-525.	0.7	2
85	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis, 2019, 290, 140-205.	0.4	1,753
86	Elevated Serum Uric Acid and Self-Reported Heart Failure in US Adults: 2007-2016 National Health and Nutrition Examination Survey. CardioRenal Medicine, 2019, 9, 344-353.	0.7	10
87	Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation, 2019, 139, e56-e528.	1.6	6,192
88	A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography. Journal of Cardiovascular Computed Tomography, 2019, 13, 99-104.	0.7	2
89	Indicaciones de los inhibidores de PCSK9 en la pr3ctica cl3nica. Recomendaciones de la Sociedad Espa3ola de Arteriosclerosis (SEA), 2019. Clínica E Investigaci3n En Arteriosclerosis, 2019, 31, 128-139.	0.4	28
90	Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis. Frontiers in Pharmacology, 2019, 10, 547.	1.6	14
91	Prescribing Patterns of Antihypertensive Medications in US Ambulatory Care Settings. Pharmacy (Basel, Switzerland), 2019, 7, 64.	0.6	1
92	TIMI risk score for secondary prevention of recurrent cardiovascular events in a real-world cohort of post-non-ST-elevation myocardial infarction patients. Postgraduate Medical Journal, 2019, 95, 372-377.	0.9	2
93	Effect of Physical Activity on Plasma PCSK9 in Subjects With High Risk for Type 2 Diabetes. Frontiers in Physiology, 2019, 10, 456.	1.3	9

#	ARTICLE	IF	CITATIONS
94	Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoprotein cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial. <i>Scientific Reports</i> , 2019, 9, 8537.	1.6	12
95	Clinical characteristics and lipid lowering treatment of patients initiated on proprotein convertase subtilisin-kexin type 9 inhibitors: a nationwide cohort study. <i>BMJ Open</i> , 2019, 9, e022702.	0.8	4
96	Current pharmacotherapeutic options for primary dyslipidemia in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1277-1288.	0.9	18
97	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2439-2450.	1.2	69
98	Evaluation and Management of the Vulnerable Plaque. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	3
99	Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019, 13, 525-537.	0.6	45
100	Lifestyle Interventions to Prevent Cardiovascular Events After Stroke and Transient Ischemic Attack. <i>Current Cardiology Reports</i> , 2019, 21, 44.	1.3	7
101	Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication. <i>Journal of Endovascular Therapy</i> , 2019, 26, 402-410.	0.8	2
102	Novel phthalamide derivatives as antihypertensive agents: rapid and clean synthesis, in silico and in vivo evaluation. <i>Medicinal Chemistry Research</i> , 2019, 28, 681-695.	1.1	2
103	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 338-356.	0.8	27
104	Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention of Recurrent Cardiovascular Events in a Real-World Cohort of Post-Acute Myocardial Infarction Patients. <i>Circulation Journal</i> , 2019, 83, 809-817.	0.7	7
105	Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. <i>Journal of the American Heart Association</i> , 2019, 8, e011662.	1.6	292
107	Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. <i>Diabetologia</i> , 2019, 62, 948-958.	2.9	41
108	Keep recycling going: New approaches to reduce LDL-C. <i>Biochemical Pharmacology</i> , 2019, 164, 336-341.	2.0	34
109	Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Case-Control Study. <i>Metabolic Syndrome and Related Disorders</i> , 2019, 17, 223-231.	0.5	9
110	Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. <i>Medical Journal of Australia</i> , 2019, 210, 80-85.	0.8	18
111	Management of dyslipidemia in adult solid organ transplant recipients. <i>Journal of Clinical Lipidology</i> , 2019, 13, 231-245.	0.6	36
112	Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 69-76.	1.3	11

#	ARTICLE	IF	CITATIONS
131	Application of PCSK9 Inhibitors in Practice. <i>Circulation Research</i> , 2019, 124, 32-37.	2.0	61
132	Drug Therapy of Dyslipidemia in the Elderly. <i>Drugs and Aging</i> , 2019, 36, 321-340.	1.3	22
133	Association of High Levels of Spot Urine Protein with High Blood Pressure, Mean Arterial Pressure and Pulse Pressure with the Development of Diabetic Chronic Kidney Dysfunction or Failure among Diabetic Patients. Statistical Regression Modeling to Predict Diabetic Proteinuria. <i>Current Diabetes Reviews</i> , 2019, 15, 486-496.	0.6	6
134	Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor. <i>Cardiology in Review</i> , 2019, 27, 49-56.	0.6	26
135	Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 173-176.	4.3	81
136	New Directions in Managing Dyslipidemia. <i>Journal for Nurse Practitioners</i> , 2019, 15, 73-79.e2.	0.4	2
137	Critical review of 2016 ACC guidelines on therapies for cholesterol lowering with reference to laboratory testing. <i>Clinica Chimica Acta</i> , 2019, 489, 189-195.	0.5	4
138	Real-World Effectiveness of High- Versus Moderate-Intensity Statin Therapy in Thai Patients With Acute Coronary Syndrome and Who Had Undergone Primary Percutaneous Coronary Intervention. <i>Journal of Pharmacy Practice</i> , 2020, 33, 640-646.	0.5	2
139	How trauma influences cardiovascular responses to stress: contributions of posttraumatic stress and cognitive appraisals. <i>Journal of Behavioral Medicine</i> , 2020, 43, 131-142.	1.1	7
140	The PCSK9 revolution: Current status, controversies, and future directions. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 179-185.	2.3	66
141	Cardiomyopathy in obesity, insulin resistance and diabetes. <i>Journal of Physiology</i> , 2020, 598, 2977-2993.	1.3	154
142	PCSK9 inhibitors and cardiovascular outcomes. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 35-47.	1.4	26
143	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	1.0	4,210
144	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	1.0	4,871
145	Risk of Cardiovascular Events in Patients With Type 2 Diabetes and Metabolic Dyslipidemia Without Prevalent Atherosclerotic Cardiovascular Disease. <i>American Journal of Medicine</i> , 2020, 133, 200-206.	0.6	6
146	Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines. <i>Kidney International</i> , 2020, 97, 266-278.	2.6	33
147	PCSK9 inhibitors: Ratification of the role of LDL cholesterol in cardiovascular prevention. Towards a convergence of European and North American prevention guidelines?. <i>Revista Clínica Española</i> , 2020, 220, 374-382.	0.3	0
148	Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized) Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 93.	1.0	1

#	ARTICLE	IF	CITATIONS
149	Non-High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History. <i>Laboratory Medicine</i> , 2020, 51, 14-23.	0.8	10
150	Have the Government's prescription algorithm and the 2013 American College of Cardiology/American Heart Association guidelines for managing dyslipidemia influenced the management of dyslipidemia? The MEJORALO-CV Project. <i>Revista Colombiana de Cardiología</i> , 2020, 220, 282-289.	0.3	0
151	Lipoprotein(a) Testing and Emerging Therapies. <i>Cardiology in Review</i> , 2020, 28, 250-255.	0.6	4
152	Mitigating Cardiovascular Risk Through User Informed Clinical Decision Support. <i>Proceedings of the International Symposium of Human Factors and Ergonomics in Healthcare</i> , 2020, 9, 67-69.	0.2	1
153	A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients. <i>Journal of Clinical Lipidology</i> , 2020, 14, 818-824.	0.6	3
154	Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-9.	0.5	14
155	Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know. <i>Annals of Translational Medicine</i> , 2020, 8, 1265-1265.	0.7	11
156	A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 1517-1528.	0.5	2
157	Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on In Vitro Hepatic Lipogenesis-Related Gene Expression. <i>Mediators of Inflammation</i> , 2020, 2020, 1-13.	1.4	7
158	Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials. <i>BMC Pharmacology & Toxicology</i> , 2020, 21, 86.	1.0	10
159	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1117-1145.	1.2	276
160	Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2137-2151.	0.9	7
161	Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 837-851.	1.5	8
162	Estimation of the major cardiovascular events prevention with Inclisiran. <i>Atherosclerosis</i> , 2020, 313, 76-80.	0.4	19
163	Women Living with Familial Hypercholesterolemia: Challenges and Considerations Surrounding Their Care. <i>Current Atherosclerosis Reports</i> , 2020, 22, 60.	2.0	32
164	Lifestyle Modification Practices and Drug Prescription Use in Elderly Americans with Metabolic Syndrome: A Nationwide Population-Based Study. <i>Journal of the National Medical Association</i> , 2020, 112, 621-631.	0.6	0
165	Windkessel Model-Based Cuffless Blood Pressure Estimation Using Continuous Wave Doppler Ultrasound System. <i>IEEE Sensors Journal</i> , 2020, 20, 9989-9999.	2.4	9
166	Goal achievement of HbA1c and LDL cholesterol in a randomized trial comparing colesevelam with ezetimibe: GOAL-RCT. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1722-1728.	2.2	6

#	ARTICLE	IF	CITATIONS
167	Hypertension prevalence in Colombian Patients Evaluated with Ambulatory Blood Pressure Monitoring According to Changes in Clinical Guidelines Between 2017-2018. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 309-313.	1.0	2
168	A new definition of gestational hypertension? New-onset blood pressures of 130 to 139/80 to 89 mm Hg after 20 weeks of gestation. American Journal of Obstetrics and Gynecology, 2020, 223, 442.e1-442.e7.	0.7	15
169	A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. Cardiology and Therapy, 2020, 9, 447-465.	1.1	6
170	Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials. Journal of Diabetes and Metabolic Disorders, 2020, 19, 759-765.	0.8	16
171	Measuring LDL-cholesterol: what is the best way to do it?. Current Opinion in Cardiology, 2020, 35, 405-411.	0.8	36
172	Eligibility for PCSK-9 inhibitors treatment in acute coronary syndrome, chronic coronary artery disease and outpatient dyslipidemic patients. Atherosclerosis, 2020, 303, 29-35.	0.4	5
173	Comparison of Renal Effects of Ezetimibe+Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis. Journal of Clinical Medicine, 2020, 9, 798.	1.0	4
174	Impact of team-based care on appropriate statin therapy prescribing in ***HIV-infected patients. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 615-622.	0.5	2
175	The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232092456.	1.1	8
176	A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 331-338.	1.0	2
177	Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nature Reviews Cardiology, 2020, 17, 585-607.	6.1	353
178	Coronary plaque tissue characterization in patients with premature coronary artery disease. International Journal of Cardiovascular Imaging, 2020, 36, 1003-1011.	0.7	10
179	Plaque morphology assessed by optical coherence tomography in the culprit lesions of the first episode of acute myocardial infarction in patients with low low-density lipoprotein cholesterol level. Journal of Cardiology, 2020, 75, 485-493.	0.8	8
180	Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	3.1	17
181	Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006019.	0.9	7
182	Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps. Journal of the American College of Cardiology, 2020, 75, 539-555.	1.2	58
183	Lipid-lowering statin therapy is beneficial in elderly female patients with hypercholesterolaemia and diabetic retinopathy. European Journal of Preventive Cardiology, 2020, , 2047487320920761.	0.8	0
184	The Associations between Liver Enzymes and Cardiovascular Risk Factors in Adults with Mild Dyslipidemia. Journal of Clinical Medicine, 2020, 9, 1147.	1.0	20

#	ARTICLE	IF	CITATIONS
185	Small Dense Low-Density Lipoprotein Cholesterol and Carotid Intimal Medial Thickness Progression. <i>Journal of Atherosclerosis and Thrombosis</i> , 2020, 27, 1108-1122.	0.9	13
186	Emerging Trends in Nanocarbon-Based Cardiovascular Applications. <i>Advanced Therapeutics</i> , 2020, 3, 1900208.	1.6	5
187	Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 833-843.	2.3	13
188	Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after proprotein convertase/subtilisin type 9 inhibitor availability. <i>Journal of Clinical Lipidology</i> , 2020, 14, 315-321.e4.	0.6	1
189	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e779-e806.	1.6	157
190	Health-related risk behaviors among myocardial infarction survivors in the United States: A propensity score matched study. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 307-314.	1.5	2
191	The prevalence of hypertension in multiple sclerosis based on 37 million electronic health records from the United States. <i>European Journal of Neurology</i> , 2021, 28, 558-566.	1.7	18
192	PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization. <i>Journal of Clinical Lipidology</i> , 2021, 15, 202-211.e2.	0.6	21
193	Advances in biological therapies for dyslipidemias and atherosclerosis. <i>Metabolism: Clinical and Experimental</i> , 2021, 116, 154461.	1.5	41
194	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1289-1367.	1.0	3,048
195	2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. <i>European Heart Journal</i> , 2021, 42, 17-96.	1.0	830
196	Posicionamento sobre o Consumo de Gorduras e SaÃde Cardiovascular â€“ 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 116, 160-212.	0.3	21
197	Comparison of demographic profile, risk factors, and in-hospital outcome in young and old patients with acute coronary syndrome: A single-center experience. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 871.	0.3	5
198	Dietary Approaches to Lowering LDL-C. <i>Contemporary Cardiology</i> , 2021, , 193-209.	0.0	0
200	Bempedoic acid: Review of a novel therapy in lipid management. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 95-104.	0.5	5
201	Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862095927.	1.0	3
202	Angiotensin-converting enzyme inhibitor activity of peptides derived from Kacang goat skin collagen through thermolysin hydrolysis. <i>Veterinary World</i> , 2021, 14, 161-167.	0.7	4
203	Economic Burden of Myocardial Infarction Combined With Dyslipidemia. <i>Frontiers in Public Health</i> , 2021, 9, 648172.	1.3	5

#	ARTICLE	IF	CITATIONS
204	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021, 319, 51-61.	0.4	37
205	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 772-810.	1.2	612
206	Statin-Associated Myalgias and Muscle Injury—Recognizing and Managing Both While Still Lowering the Low-Density Lipoprotein. <i>Medical Clinics of North America</i> , 2021, 105, 263-272.	1.1	1
207	The Clinician's Guide to the Machine Learning Galaxy. <i>Frontiers in Physiology</i> , 2021, 12, 658583.	1.3	3
208	Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e019331.	1.6	19
209	Measuring Hypertension Progression With Transition Probabilities: Estimates From the WHO SAGE Longitudinal Study. <i>Frontiers in Public Health</i> , 2021, 9, 571110.	1.3	5
210	Umbrella Review on Non-Statins Lipid-Lowering Therapy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110029.	1.0	11
211	Deleterious side effects of nutritional supplements. <i>Clinics in Dermatology</i> , 2021, 39, 745-756.	0.8	3
212	Is the SMART risk prediction model ready for real-world implementation? A validation study in a routine care setting of approximately 380 000 individuals. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 654-663.	0.8	11
215	The Society for Vascular Surgery implementation document for management of extracranial cerebrovascular disease. <i>Journal of Vascular Surgery</i> , 2022, 75, 26S-98S.	0.6	66
216	Pharmacological Management of Hyperlipidemia in Older Individuals. , 2021, 36, 284-303.		1
217	Maternal first antenatal care visit biometric indices as potential predictors of umbilical cord morphometric parameters. <i>Journal of Neonatal-Perinatal Medicine</i> , 2021, , 1-8.	0.4	1
218	An exploratory survey on the awareness and usage of clinical practice guidelines among clinical pharmacists. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 2, 100013.	0.6	0
219	Chronic Kidney Disease and Cerebrovascular Disease. <i>Stroke</i> , 2021, 52, e328-e346.	1.0	56
220	Right ventricular systolic and diastolic function in heart failure with preserved ejection fraction. <i>Cor Et Vasa</i> , 2021, 63, 295-303.	0.1	0
221	INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions. <i>Current Cardiology Reports</i> , 2021, 23, 136.	1.3	5
222	Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 3828.	1.0	9
223	The Relationship Between Serum Uric Acid at Different Concentrations of Lipid Indices and the Risk of Myocardial Revascularization in Patients With Acute Coronary Syndrome: A Retrospective Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 732715.	1.1	1

#	ARTICLE	IF	CITATIONS
224	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes) Tj ETQq0000 rgBT3Overlock	0.3	0
225	Dyslipidemia: Current Therapies and Strategies to Overcome Barriers for Use. Journal for Nurse Practitioners, 2021, , .	0.4	2
226	Inhibidores de PCSK9: ratificaci3n del papel del colesterol LDL en prevenci3n cardiovascular. ¿Hacia la convergencia en las guAs de prevenci3n europeas y norteamericanas?. Revista Clinica Espanola, 2020, 220, 374-382.	0.2	5
227	¿Han influido el algoritmo de prescripci3n de la Administraci3n y las guAs de manejo de la dislipemia de la ACC/AHA 2013 en el manejo de la dislipemia? Proyecto MEJORA-LO CV. Revista Clínica Espanola, 2020, 220, 282-289.	0.2	1
228	Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective. Singapore Medical Journal, 2016, 57, 360-367.	0.3	6
229	Poststatin Lipid Therapeutics: A Review. Methodist DeBakey Cardiovascular Journal, 2021, 15, 32.	0.5	8
230	Increase in high-sensitive C-reactive protein as a marker of polyvascular disease in patients with cardiovascular diseases. Meditsinskiy Sovet, 2019, , 86-93.	0.1	3
231	Molecular Insights into the Mechanisms Underlying the Cholesterol- Lowering Effects of Phytosterols. Current Medicinal Chemistry, 2019, 26, 6704-6723.	1.2	40
232	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. Current Drug Metabolism, 2019, 20, 72-82.	0.7	12
233	Diabetes and Mortality in Acute Coronary Syndrome: Findings from the Gulf COAST Registry. Current Vascular Pharmacology, 2019, 18, 68-76.	0.8	10
234	Deep Neural Network for Reducing the Screening Workload in Systematic Reviews for Clinical Guidelines: Algorithm Validation Study. Journal of Medical Internet Research, 2020, 22, e22422.	2.1	11
235	Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction. Diabetes and Metabolism Journal, 2020, 44, 213.	1.8	43
236	Cardiovascular prevention: Frontiers in lipid guidelines. Clinical Medicine, 2020, 20, 36-42.	0.8	6
237	Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease. International Journal of Molecular Sciences, 2021, 22, 11179.	1.8	30
238	State of the Care, Definition, and Epidemiology of Chronic Kidney Disease. , 2022, , 11-24.		1
239	Predictors of Quality of Life in Patients With Myocardial Infarction Combined With Dyslipidemia. Frontiers in Public Health, 2021, 9, 713480.	1.3	4
240	Stable Ischemic Heart Disease. , 2017, , .		0
241	Hyperlipidemia. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
242	Dyslipidemia. , 2017, , .		0
243	Hypertension. What do new guides bring up to date?. Medic Ro, 2018, 4, 36.	0.0	0
244	Lack of accurate evidence on non-statin medication in patients receiving highintensity statin therapy: Re-evaluation of recommendations is needed. Anatolian Journal of Cardiology, 2018, 19, 230.	0.5	0
245	The year in cardiology 2017: prevention. Cardiologia Croatica, 2018, 13, 79-98.	0.0	0
246	Relation of smoking and endothelial dysfunction markers in systemic hypertension. Cardiovascular Therapy and Prevention (Russian Federation), 2018, 17, 11-16.	0.4	3
247	How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines. Methodist DeBakey Cardiovascular Journal, 2021, 15, 16.	0.5	1
248	PCSK9 Inhibition with Evolocumab Reaching Physiologic LDL-C Levels for Reducing Atherosclerotic Burden and Cardiovascular Disease-The Full Landscape. Frontiers in Cardiovascular Drug Discovery, 2019, , 148-185.	0.0	0
250	Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of Contemporary Pharmacy Practice, 2019, 66, 54-63.	0.2	1
251	Fixeddose combination of rosuvastatin + ezetimibe: ease of use, safety and efficacy. Meditsinskiy Sovet, 2019, , 21-26.	0.1	2
252	Prevalence and Associated Factors of Hypertension Subtypes Among the Adult Population in Nepal: Evidence from Demographic and Health Survey Data. Osong Public Health and Research Perspectives, 2019, 10, 327-336.	0.7	3
253	The Allied Health Professionalâ€™s Role in the Management of Dyslipidemia and Accreditation Council for Clinical Lipidology Certification Program. Contemporary Cardiology, 2021, , 637-664.	0.0	1
254	SIDE EFFECTS CORRECTION IN COMBINED LIPID-CORRECTING THERAPY WITH STATINS AND FIBRATES USING LOW-MINERALIZED MINERAL WATER. World of Medicine and Biology, 2020, 16, 53.	0.1	0
255	Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review. Current Cardiology Reviews, 2020, 16, 36-47.	0.6	9
256	Low-Density Lipoprotein Cholesterol is Inversely Associated with All-Cause Mortality of Patients in the Coronary Care Unit. International Journal of General Medicine, 2021, Volume 14, 7659-7667.	0.8	1
258	Group-Based Trajectory Models to Identify Sociodemographic and Clinical Predictors of Adherence Patterns to Statin Therapy Among Older Adults. American Health and Drug Benefits, 2019, 12, 202-211.	0.5	11
259	The Key Role of Ambulatory Blood Pressure Monitoring in the Detection of Masked Hypertension and Other Phenomena in Frail Geriatric Patients. Medicina (Lithuania), 2021, 57, 1221.	0.8	1
260	An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease. Expert Opinion on Drug Metabolism and Toxicology, 2022, , 1-9.	1.5	7
261	Impacto de la Pandemia por COVID19 en el control lipÃ©dico de pacientes que inician inhibidores de la PCSK9. CIÃ©nica E InvestigaciÃ³n En Arteriosclerosis, 2022, , .	0.4	2

#	ARTICLE	IF	CITATIONS
264	Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance. <i>Neurología (English Edition)</i> , 2022, 37, 136-150.	0.2	3
265	Statin-associated muscle symptoms: A review: Individualizing the approach to optimize care. <i>Pharmacotherapy</i> , 2022, 42, 428-438.	1.2	10
266	Statin-Associated Myalgias and Muscle Injury: Recognizing and Managing Both While Still Lowering the Low-Density Lipoprotein. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 445-454.	0.8	1
267	Chapter 15: Ischemic Heart Disease and Acute Coronary Syndrome. , 2022, , .		0
270	The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy. , 2022, 13, 491.		17
271	Clinical strategies for reducing cholesterol levels. , 2022, , 853-901.		0
272	Clinical significance of N-terminal natriuretic peptide combined with inflammatory factors, oxidative stress factors and blood lipid detection in elderly patients with Type-2 diabetes complicated with coronary heart disease. <i>Pakistan Journal of Medical Sciences</i> , 2022, 38, .	0.3	0
274	Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies. <i>PLoS ONE</i> , 2022, 17, e0264563.	1.1	4
275	Dietary Plant Sterols and Phytosterol-Enriched Margarines and Their Relationship with Cardiovascular Disease among Polish Men and Women: The WOBASZ II Cross-Sectional Study. <i>Nutrients</i> , 2022, 14, 2665.	1.7	11
277	Lipid Lowering Therapy: An Era Beyond Statins. <i>Current Problems in Cardiology</i> , 2022, 47, 101342.	1.1	24
278	Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6
279	2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1366-1418.	1.2	147
280	Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors. <i>Clínica e Investigación en Arteriosclerosis (English Edition)</i> , 2022, , .	0.1	0
281	Association of Variants of the <i>NFE2L2</i> Gene with Metabolic and Kidney Function Parameters in Patients with Diabetes and/or Hypertension. <i>Genetic Testing and Molecular Biomarkers</i> , 2022, 26, 382-390.	0.3	3
282	Accuracy of the Number Needed to Treat Compared With Diagnostic Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, , .	1.2	0
283	Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients. <i>Clinical and Translational Science</i> , 2022, 15, 2858-2867.	1.5	1
284	A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines. <i>Vaccines</i> , 2023, 11, 2.	2.1	5
285	Statin intolerance management: a systematic review. <i>Endocrine</i> , 2023, 79, 430-436.	1.1	3

#	ARTICLE	IF	CITATIONS
286	The Generation of Nitric Oxide from Aldehyde Dehydrogenase-2: The Role of Dietary Nitrates and Their Implication in Cardiovascular Disease Management. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15454.	1.8	3
287	Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
288	An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors. <i>Cardiovascular Therapeutics</i> , 2023, 2023, 1-11.	1.1	8
289	Best practice for LDL-cholesterol: when and how to calculate. <i>Journal of Clinical Pathology</i> , 2023, 76, 145-152.	1.0	11
291	Consensus Recommendations of the Asia Pacific Cardiometabolic Consortium on Secondary Prevention Strategies in Myocardial Infarction: Recommendations on Pharmacotherapy, Lifestyle Modification and Cardiac Rehabilitation. , 0, 2, .		1
292	Administration of macrolide antibiotics increases cardiovascular risk. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	2
297	Overview of General Approach to Management of Dyslipidemias. , 2024, , 97-100.e1.		0
302	Antimicrobial activity of <i>Penicillium</i> species metabolites. , 2024, , 369-383.		0
305	Cerebrovascular Disease and Chronic Kidney Disease. , 2023, , 199-213.		0
310	Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature. <i>Drugs</i> , 2024, 84, 165-178.	4.9	0